Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime E C Hallak

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Journal of Psychopharmacology (Oxford, England)|May 31, 2026
Classic psychedelics and personality: An updated systematic reviewAnna Beatriz Vicentini, Caio César de Paula, José Augusto Silva Reis, et al.
Journal of Psychopharmacology (Oxford, England)|January 13, 2006
Cannabidiol monotherapy for treatment-resistant schizophreniaAntonio Waldo Zuardi, Jaime E C Hallak, Serdar Murat Dursun, et al.
Frontiers in Pharmacology|May 30, 2017
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real LifeAntonio W Zuardi, Natália P Rodrigues, Angélica L Silva, et al.
Drug and Alcohol Review|December 1, 2022
Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiencesBorja J Rodríguez-Cano, Maja Kohek, Genís Ona, et al.
Frontiers in Pharmacology|July 10, 2025
Ketogenic therapy for schizophrenia: evidence, mechanisms, and clinical perspectivesCristiano Chaves, Jennifer Fabe, Fabiano A Gomes, et al.
Psychopharmacology|October 29, 2020
Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trialRichard J Zeifman, Nikhita Singhal, Rafael G Dos Santos, et al.
Toxicology and Applied Pharmacology|April 5, 2026
Early-life exposure to Cannabidiol: Safety assessment of a chronic exposure in Caenorhabditis elegansHeloísa Aiolfi Padilha, Jean Freitas Reginatto, Júlia Dorneles Saleh, et al.
Talanta|February 17, 2021
Essential oil-based dispersive liquid-liquid microextraction for the determination of N,N-dimethyltryptamine and β-carbolines in human plasma: A novel solvent-free alternativeGabriela de Oliveira Silveira, Felipe Rebello Lourenço, Ana Miguel Fonseca Pego, et al.
Current Pharmaceutical Design|June 22, 2012
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigationAntonio Waldo Zuardi, Jose Alexandre S Crippa, Jaime E C Hallak, et al.
Scientific Reports|March 7, 2020
Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combinationDaniel F Jiménez-Garrido, María Gómez-Sousa, Genís Ona, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Journal of Psychopharmacology (Oxford, England)|May 31, 2026
Classic psychedelics and personality: An updated systematic reviewAnna Beatriz Vicentini, Caio César de Paula, José Augusto Silva Reis, et al.
Journal of Psychopharmacology (Oxford, England)|January 13, 2006
Cannabidiol monotherapy for treatment-resistant schizophreniaAntonio Waldo Zuardi, Jaime E C Hallak, Serdar Murat Dursun, et al.
Frontiers in Pharmacology|May 30, 2017
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real LifeAntonio W Zuardi, Natália P Rodrigues, Angélica L Silva, et al.
Drug and Alcohol Review|December 1, 2022
Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiencesBorja J Rodríguez-Cano, Maja Kohek, Genís Ona, et al.
Frontiers in Pharmacology|July 10, 2025
Ketogenic therapy for schizophrenia: evidence, mechanisms, and clinical perspectivesCristiano Chaves, Jennifer Fabe, Fabiano A Gomes, et al.
Psychopharmacology|October 29, 2020
Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trialRichard J Zeifman, Nikhita Singhal, Rafael G Dos Santos, et al.
Toxicology and Applied Pharmacology|April 5, 2026
Early-life exposure to Cannabidiol: Safety assessment of a chronic exposure in Caenorhabditis elegansHeloísa Aiolfi Padilha, Jean Freitas Reginatto, Júlia Dorneles Saleh, et al.
Talanta|February 17, 2021
Essential oil-based dispersive liquid-liquid microextraction for the determination of N,N-dimethyltryptamine and β-carbolines in human plasma: A novel solvent-free alternativeGabriela de Oliveira Silveira, Felipe Rebello Lourenço, Ana Miguel Fonseca Pego, et al.
Current Pharmaceutical Design|June 22, 2012
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigationAntonio Waldo Zuardi, Jose Alexandre S Crippa, Jaime E C Hallak, et al.
Scientific Reports|March 7, 2020
Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combinationDaniel F Jiménez-Garrido, María Gómez-Sousa, Genís Ona, et al.
Pageof 13